close
MENU
Hot Topic Hawke’s Bay
Hot Topic Hawke’s Bay
3 mins to read

There will be more Nurofen cases, lawyer says

Updated, with special feature audio: Will “natural health remedies" also come under scrutiny?

Campbell Gibson and Paul McBeth
Wed, 28 Sep 2016

The Commerce Commission’s crack down on misleading product promotion is welcome news and more companies and sectors are likely to come under scrutiny, says Auckland lawyer Steve Dukeson.

This week Nurofen felt the hot breath of the commission with consumer goods giant Reckitt Benckiser signalling it would plead guilty to 10 charges brought over the way it promoted a range of the painkiller products.

“In relation to companies that are pleading guilty to charges of misleading conduct, I think you are entitled to conclude their conduct is unacceptable and we deserve better,” Mr Dukeson told NBR Radio’s Andrew Patterson.

He suggests "natural health remedies" could come under scrutiny, especially in light of new laws relating to making unsubstantiated representations.

“I have heard during this year about medical investigators in Britain who found no evidence that most natural health products have any benefit at all or they just simply don’t work. It’s not good enough to make statements without some degree of proof, some degree of evidence.”

Mr Dukeson’s comments follow similar remarks from Consumer NZ research writer Jessica Wilson Consumer NZ, who says Reckitt Benckiser is not alone.

She says other drug companies often make a slight change to the composition of their drugs and market them as a different product.

EARLIER 26/9: Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says.

The regulator brought 10 charges under the Fair Trading Act against the local division of the consumer goods business, eight of which claim the packaging and promotion of four Nurofen products were misleading, and two that the online advertising of the range was likely to mislead or deceive consumers, it said in a statement. The commission said Reckitt Benckiser had cooperated with the investigation and intended to plead guilty to the charges.

On its websites and retail packaging, the multi-billion dollar consumer goods giant claimed the products – Nurofen Back Pain, Period Pain, Migraine Pain and Tension Headache – were formulated to treat a particular type of pain.

However, all four products contained the same active ingredient, ibuprofen lysine 342mg.

"The commission alleges that both the website and the packaging of these products gave the overall impression that the products were targeted to provide relief for a specific kind of pain," it said. "The commission alleges this was misleading because the pain specific products contained the same ingredients and were equally effective in treating any of the types of pain specified."

Reckitt Benckiser had already agreed to enforceable undertakings to change the packaging of the specific pain range and had taken down the offending website pages prior to that.

The regulator's probe began after the Australian Competition and Consumer Commission won a case against Reckitt Benckiser for misleading consumers with the painkiller's packaging. The ACCC is appealing the A$1.7 million fine imposed as being too small, with a hearing scheduled for November.

In a separate statement, the company said the products accounted for just 5 percent of the New Zealand Nurofen range, and that all Nurofen products with the same active ingredient, pack-size, format and formulation carry the same recommended retail price.

"This court action applies to New Zealand only and does not apply to other countries/regions or to other products in the Nurofen range," it said.

Reckitt Benckiser reported sales of $127.8 million in calendar 2015, though the slashing of goodwill pushed earnings to a loss of $48.8 million. The consumer goods firm cut $51.8 million from goodwill - which represents the premium paid over the fair value of identifiable assets in an acquisition - valuing the intangible asset at $79.4 million as at Dec. 31.

Both the regulator and the company said they wouldn't comment further because the matter is before the courts.

(BusinessDesk)

Click the hamburger symbol top right of our homepage to access the Rich List 2016 and other sections.

Campbell Gibson and Paul McBeth
Wed, 28 Sep 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
There will be more Nurofen cases, lawyer says
61900
false